Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael M Lederman

Showing results (161-170 of 303) with videos related to

Pageof 31
Sort By:
Journal of Virus Eradication|March 10, 2017
Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patientsMaura Manion, Bruno B Andrade, Rebecca DerSimonian, et al.
Blood|October 16, 2012
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromeNicholas T Funderburg, David A Zidar, Carey Shive, et al.
The Journal of Infectious Diseases|July 12, 2012
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfectionDonald D Anthony, Sara J Conry, Kathy Medvik, et al.
Science Advances|December 19, 2025
Interleukin-2 is a potent latency reversal agent in people with treated HIV-1Michael L Freeman, Brian M Clagett, Konstantin Leskov, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|August 17, 2005
New entrants to HIV care are presenting only at marginally earlier stages of disease but may increasingly represent groups perceived at lower riskChariclia V Loupa, Michael M Lederman, Hernán Valdez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2018
Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral SuppressionMartin Hoenigl, Carlee B Moser, Nicholas Funderburg, et al.
Open Forum Infectious Diseases|March 2, 2023
Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare WorkersMichael L Freeman, Oladayo A Oyebanji, Daniela Moisi, et al.
Frontiers in Immunology|September 13, 2024
Elevated plasma levels of IP-10 and MIG are early predictors of loss of control among elite HIV controllersEva Poveda, Wendy Fitzgerald, Jacobo Alonso-Domínguez, et al.
Plos One|April 6, 2012
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trialJonathan Z Li, Chanson J Brumme, Michael M Lederman, et al.
AIDS Research and Therapy|March 24, 2017
Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individualsJan Weber, Richard M Gibson, Lenka Sácká, et al.
Pageof 31

Showing results (161-170 of 303) with videos related to

Sort By:
Pageof 31
Journal of Virus Eradication|March 10, 2017
Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patientsMaura Manion, Bruno B Andrade, Rebecca DerSimonian, et al.
Blood|October 16, 2012
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromeNicholas T Funderburg, David A Zidar, Carey Shive, et al.
The Journal of Infectious Diseases|July 12, 2012
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfectionDonald D Anthony, Sara J Conry, Kathy Medvik, et al.
Science Advances|December 19, 2025
Interleukin-2 is a potent latency reversal agent in people with treated HIV-1Michael L Freeman, Brian M Clagett, Konstantin Leskov, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|August 17, 2005
New entrants to HIV care are presenting only at marginally earlier stages of disease but may increasingly represent groups perceived at lower riskChariclia V Loupa, Michael M Lederman, Hernán Valdez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2018
Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral SuppressionMartin Hoenigl, Carlee B Moser, Nicholas Funderburg, et al.
Open Forum Infectious Diseases|March 2, 2023
Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare WorkersMichael L Freeman, Oladayo A Oyebanji, Daniela Moisi, et al.
Frontiers in Immunology|September 13, 2024
Elevated plasma levels of IP-10 and MIG are early predictors of loss of control among elite HIV controllersEva Poveda, Wendy Fitzgerald, Jacobo Alonso-Domínguez, et al.
Plos One|April 6, 2012
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trialJonathan Z Li, Chanson J Brumme, Michael M Lederman, et al.
AIDS Research and Therapy|March 24, 2017
Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individualsJan Weber, Richard M Gibson, Lenka Sácká, et al.
Pageof 31